Loucks Tammy L, Tyson Clare, Dorr David, Garovic Vesna D, Hill James, McSwain S David, Radovick Sally, Sonnenberg Frank A, Weis Jennifer A, Brady Kathleen T
South Carolina Clinical and Translational Research (SCTR) Institute, Medical University of South Carolina, Charleston, SC, USA.
Department of Medical Informatics and Clinical Epidemiology, Oregon Health and Science University, Portland, OR, USA.
J Clin Transl Sci. 2021 Mar 8;5(1):e102. doi: 10.1017/cts.2021.19.
Clinical trials are a fundamental tool in evaluating the safety and efficacy of new drugs, medical devices, and health system interventions. Clinical trial visits generally involve eligibility assessment, enrollment, intervention administration, data collection, and follow-up, with many of these steps performed during face-to-face visits between participants and the investigative team. Social distancing, which emerged as one of the mainstay strategies for reducing the spread of SARS-CoV-2, has presented a challenge to the traditional model of clinical trial conduct, causing many research teams to halt all in-person contacts except for life-saving research. Nonetheless, clinical research has continued during the pandemic because study teams adapted quickly, turning to virtual visits and other similar methods to complete critical research activities. The purpose of this special communication is to document this rapid transition to virtual methodologies at Clinical and Translational Science Awards hubs and highlight important considerations for future development. Looking beyond the pandemic, we envision that a hybrid approach, which implements remote activities when feasible but also maintains in-person activities as necessary, will be adopted more widely for clinical trials. There will always be a need for in-person aspects of clinical research, but future study designs will need to incorporate remote capabilities.
临床试验是评估新药、医疗器械和卫生系统干预措施的安全性和有效性的基本工具。临床试验访视通常包括资格评估、入组、干预措施实施、数据收集和随访,其中许多步骤是在参与者与研究团队的面对面访视期间进行的。社交距离作为减少严重急性呼吸综合征冠状病毒2(SARS-CoV-2)传播的主要策略之一出现后,给传统的临床试验开展模式带来了挑战,导致许多研究团队停止了除挽救生命的研究之外的所有面对面接触。尽管如此,临床研究在疫情期间仍在继续,因为研究团队迅速做出调整,转向虚拟访视和其他类似方法来完成关键的研究活动。本特别通讯的目的是记录临床与转化科学奖中心向虚拟方法的快速转变,并强调未来发展的重要考虑因素。展望疫情之后,我们设想一种混合方法将在临床试验中得到更广泛的采用,这种方法在可行时实施远程活动,但也在必要时保留面对面活动。临床研究始终需要面对面的环节,但未来的研究设计将需要纳入远程能力。